These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 22337247

  • 1. Characterization of patients with arthritis referred for gold therapy in the era of biologics.
    Cheung JM, Scarsbrook D, Klinkhoff AV.
    J Rheumatol; 2012 Apr; 39(4):716-9. PubMed ID: 22337247
    [Abstract] [Full Text] [Related]

  • 2. [Descriptive study of the use of DMARD in patients with rheumatoid arthritis or persistent arthritis who start drug treatment in Spain (FIRST)].
    Blanco FJ, Ballina J, Carbonell J, Martín-Mola E, Tornero J, Ramírez E, Galván J.
    Reumatol Clin; 2011 Apr; 7(2):88-93. PubMed ID: 21794790
    [Abstract] [Full Text] [Related]

  • 3. The second course of gold.
    Klinkhoff AV, Teufel A.
    J Rheumatol; 1995 Sep; 22(9):1655-6. PubMed ID: 8523339
    [Abstract] [Full Text] [Related]

  • 4. First-time prescriptions of biological disease-modifying antirheumatic drugs in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis 2002-2011: data from the NOR-DMARD register.
    Lie E, Fagerli KM, Mikkelsen K, Rødevand E, Lexberg A, Kalstad S, Uhlig T, Kvien TK.
    Ann Rheum Dis; 2014 Oct; 73(10):1905-6. PubMed ID: 24989896
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Gold therapy in women planning pregnancy: outcomes in one center.
    Almarzouqi M, Scarsbrook D, Klinkhoff A.
    J Rheumatol; 2007 Sep; 34(9):1827-31. PubMed ID: 17696276
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Gold preparations in therapy of rheumatoid and psoriatic arthritis].
    Nasonova VA, Lukina GV, Sigidin IaA, Badokin VV.
    Ter Arkh; 2003 Sep; 75(5):88-90. PubMed ID: 12847908
    [No Abstract] [Full Text] [Related]

  • 9. Juvenile idiopathic arthritis--current and future therapies.
    Kahn P.
    Bull NYU Hosp Jt Dis; 2009 Sep; 67(3):291-302. PubMed ID: 19852753
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis.
    Maradit-Kremers H, Nicola PJ, Crowson CS, O'Fallon WM, Gabriel SE.
    J Rheumatol; 2006 Feb; 33(2):248-55. PubMed ID: 16358365
    [Abstract] [Full Text] [Related]

  • 13. Patterns of disease modifying antirheumatic drug use in a Spanish cohort of patients with rheumatoid arthritis.
    Gonzalez-Alvaro I, Carmona L, Balsa A, Sanmarti R, Belmonte MA, Tena X, EMECAR Study Group.
    J Rheumatol; 2003 Apr; 30(4):697-704. PubMed ID: 12672186
    [Abstract] [Full Text] [Related]

  • 14. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study.
    Gibofsky A, Palmer WR, Goldman JA, Lautzenheiser RL, Markenson JA, Weaver A, Schiff MH, Keystone EC, Paulus HE, Harrison MJ, Whitmore JB, Leff JA.
    Curr Med Res Opin; 2006 Jan; 22(1):169-83. PubMed ID: 16393443
    [Abstract] [Full Text] [Related]

  • 15. Time to consultation and disease-modifying antirheumatic drug treatment of patients with rheumatoid arthritis--northern Alberta perspective.
    Nanji JA, Choi M, Ferrari R, Lyddell C, Russell AS.
    J Rheumatol; 2012 Apr; 39(4):707-11. PubMed ID: 22337235
    [Abstract] [Full Text] [Related]

  • 16. Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs.
    Malysheva OA, Wahle M, Wagner U, Pierer M, Arnold S, Häntzschel H, Baerwald CG.
    J Rheumatol; 2008 Jun; 35(6):979-85. PubMed ID: 18412314
    [Abstract] [Full Text] [Related]

  • 17. Disappointing longterm results with disease modifying antirheumatic drugs. A practice based study.
    Galindo-Rodriguez G, Aviña-Zubieta JA, Russell AS, Suarez-Almazor ME.
    J Rheumatol; 1999 Nov; 26(11):2337-43. PubMed ID: 10555887
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD.
    Cannon GW, Holden WL, Juhaeri J, Dai W, Scarazzini L, Stang P.
    J Rheumatol; 2004 Oct; 31(10):1906-11. PubMed ID: 15468352
    [Abstract] [Full Text] [Related]

  • 20. Remission in rheumatoid arthritis: wishful thinking or clinical reality?
    Sesin CA, Bingham CO.
    Semin Arthritis Rheum; 2005 Dec; 35(3):185-96. PubMed ID: 16325659
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.